选择性BCL-2抑制剂通过诱导mtDNA释放触发了STING-依赖的抗瘤免疫
Wenxin Zhang1, Xiaohui Pan1, Longsheng Wang1
1College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
Journal for immunotherapy of cancer
|April 29, 2025
概括
ABT-199通过诱导线粒体DNA释放,增强抗瘤免疫力和与抗PD-L1疗法的协同作用来激活干扰素基因刺激器 (STING) 途径. 这为癌症免疫疗法中的STING激活提供了一个新的小分子.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 干扰素基因刺激器 (STING) 途径对癌症免疫力和瘤微环境调节至关重要,使其成为癌症免疫治疗的关键目标.
- 虽然STING激动剂显示出希望,但大多数都处于早期临床试验阶段,这凸显了需要易于获得的小分子的需求.
- 已确定ABT-199是一种能够激活STING通路以增强免疫治疗效果的小分子.
研究的目的:
- 研究ABT-199在结直肠癌细胞中的STING信号通路的激活.
- 评估ABT-199,单独或与抗PD-L1疗法结合的体内治疗效果.
- 阐明ABT-199诱导的STING激活背后的分子机制,重点关注VDAC1寡合化和mtDNA释放.
主要方法:
- 通过酸化STING,TBK1和IRF3以及IFN-I信号,评估了STING通路的激活.
- 在小鼠皮下瘤中使用ABT-199和抗PD-L1组合评估体内疗效.
- 使用流式细胞计,ELISA,免疫光学,qPCR,化学交叉链接,共免疫沉和CRISPR/Cas9来研究分子机制.
主要成果:
- 在结直肠癌细胞中,ABT-199显著激活了STING通路,增加了TBK1/IRF3酸化和化学因子表达 (CCL5,CXCL10).
- 通过增强细胞毒性T细胞透,ABT-199促进了抗瘤免疫力,并与抗PD-L1疗法协同.
- ABT-199通过细胞质mtDNA释放诱导了STING激活,由VDAC1寡合化中介,破坏了BCL-2相互作用.
结论:
- ABT-199是用于STING激活的准备使用的小分子,为癌症免疫治疗提供了一个新的途径.
- 该研究揭示了ABT-199的作用机制,涉及VDAC1-介导的mtDNA释放和随后的STING通路激活.
- 这些发现为在临床癌症免疫治疗策略中利用ABT-199提供了坚实的理论基础.
更多相关视频
07:09Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
Published on: January 7, 2019
7.4K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.6K
相关概念视频
The Intrinsic Apoptotic Pathway
5.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cytotoxic T Cells-mediated Immune Response
731
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
731
Tumor Immunotherapy
401
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
401
The Extrinsic Apoptotic Pathway
5.5K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
5.5K
